Aldose reductase as a regulator of ocular pathology: Mechanisms and therapeutic potential

Area of Science:

• Biochemistry
• Ophthalmology
• Pharmacology

Background:

• Aldose reductase (AR) is the key enzyme in the polyol pathway, converting glucose to sorbitol.
• Hyperglycemia significantly increases AR activity, leading to sorbitol accumulation in ocular tissues.
• AR dysfunction is implicated in the pathogenesis of diabetic retinopathy, cataracts, glaucoma, and optic neuropathies.

Purpose of the Study:

• To elucidate the role of aldose reductase in the development of ocular diseases.
• To highlight the therapeutic potential of targeting the polyol pathway for vision preservation.

Main Methods:

• Review of biochemical pathways and cellular mechanisms.
• Analysis of the contribution of aldose reductase to ocular pathology.
• Evaluation of aldose reductase inhibitors (ARIs) as therapeutic agents.

Main Results:

• AR overactivity under hyperglycemia leads to sorbitol accumulation, NADPH depletion, oxidative stress, and microglial activation.
• These molecular events contribute to the progression of diabetic retinopathy, cataract, glaucoma, and optic neuropathies.
• ARIs have demonstrated efficacy in reducing sorbitol, oxidative stress, VEGF expression, and microglial activation.

Conclusions:

• Aldose reductase plays a critical role in the pathogenesis of multiple vision-threatening ocular diseases.
• Targeting aldose reductase presents a promising therapeutic avenue for preventing or slowing the progression of these conditions.